疑难病杂志
疑難病雜誌
의난병잡지
JOURNAL OF DIFFICULT AND COMPLICATED CASES
2015年
9期
891-894
,共4页
毕贞水%颜景红%王正凯%梁斌
畢貞水%顏景紅%王正凱%樑斌
필정수%안경홍%왕정개%량빈
慢性阻塞性肺疾病%连花清瘟胶囊%肺功能%血气指标%炎性因子
慢性阻塞性肺疾病%連花清瘟膠囊%肺功能%血氣指標%炎性因子
만성조새성폐질병%련화청온효낭%폐공능%혈기지표%염성인자
Chronic obstructive pulmonary disease%Lianhuaqingwen capsules%Pulmonary function%Blood gas index%Inflammatory factor
目的:探讨连花清瘟胶囊治疗慢性阻塞性肺疾病患者临床效果及其对肺功能、血气指标及炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)和白细胞素素-17(IL-17)]水平的影响。方法选择2014年1月—2015年2月内科住院或门诊治疗的慢性阻塞性肺疾病患者72例,按随机数字表法分为2组,每组36例。对照组给予常规治疗,观察组在对照组基础上加服连花清瘟胶囊;治疗10 d后观察2组患者临床疗效、肺功能、血气指标及TNF-α、IL-8和IL-17水平变化。结果观察组总有效率显著高于对照组(94.4%vs 72.2%,χ2=17.71, P <0.05)。治疗后2组患者肺功能指标、第1秒用力呼气容积( FEV1)、第1秒用力呼气容积专用力肺活量比值( FEV1/FVC)、血气指标[动脉血氧分压( PaO2)、二氧化碳分压( PaCO2)]、TNF-α、IL-8和IL-17水平较治疗前显著改善,差异具有统计学意义( P <0.05);且观察组改善程度优于对照组,差异具有统计学意义( P <0.05)。2组治疗前后pH值均无明显变化(P >0.05),治疗期间2组患者血压、心率、肝肾功能及血、尿常规均未发生明显改变,无其他不良反应。结论连花清瘟胶囊能显著改善慢性阻塞性肺疾病患者的临床疗效,能有效抑制炎性因子释放,从而减轻气道炎性反应作用。
目的:探討連花清瘟膠囊治療慢性阻塞性肺疾病患者臨床效果及其對肺功能、血氣指標及炎性因子[腫瘤壞死因子-α(TNF-α)、白細胞介素-8(IL-8)和白細胞素素-17(IL-17)]水平的影響。方法選擇2014年1月—2015年2月內科住院或門診治療的慢性阻塞性肺疾病患者72例,按隨機數字錶法分為2組,每組36例。對照組給予常規治療,觀察組在對照組基礎上加服連花清瘟膠囊;治療10 d後觀察2組患者臨床療效、肺功能、血氣指標及TNF-α、IL-8和IL-17水平變化。結果觀察組總有效率顯著高于對照組(94.4%vs 72.2%,χ2=17.71, P <0.05)。治療後2組患者肺功能指標、第1秒用力呼氣容積( FEV1)、第1秒用力呼氣容積專用力肺活量比值( FEV1/FVC)、血氣指標[動脈血氧分壓( PaO2)、二氧化碳分壓( PaCO2)]、TNF-α、IL-8和IL-17水平較治療前顯著改善,差異具有統計學意義( P <0.05);且觀察組改善程度優于對照組,差異具有統計學意義( P <0.05)。2組治療前後pH值均無明顯變化(P >0.05),治療期間2組患者血壓、心率、肝腎功能及血、尿常規均未髮生明顯改變,無其他不良反應。結論連花清瘟膠囊能顯著改善慢性阻塞性肺疾病患者的臨床療效,能有效抑製炎性因子釋放,從而減輕氣道炎性反應作用。
목적:탐토련화청온효낭치료만성조새성폐질병환자림상효과급기대폐공능、혈기지표급염성인자[종류배사인자-α(TNF-α)、백세포개소-8(IL-8)화백세포소소-17(IL-17)]수평적영향。방법선택2014년1월—2015년2월내과주원혹문진치료적만성조새성폐질병환자72례,안수궤수자표법분위2조,매조36례。대조조급여상규치료,관찰조재대조조기출상가복련화청온효낭;치료10 d후관찰2조환자림상료효、폐공능、혈기지표급TNF-α、IL-8화IL-17수평변화。결과관찰조총유효솔현저고우대조조(94.4%vs 72.2%,χ2=17.71, P <0.05)。치료후2조환자폐공능지표、제1초용력호기용적( FEV1)、제1초용력호기용적전용력폐활량비치( FEV1/FVC)、혈기지표[동맥혈양분압( PaO2)、이양화탄분압( PaCO2)]、TNF-α、IL-8화IL-17수평교치료전현저개선,차이구유통계학의의( P <0.05);차관찰조개선정도우우대조조,차이구유통계학의의( P <0.05)。2조치료전후pH치균무명현변화(P >0.05),치료기간2조환자혈압、심솔、간신공능급혈、뇨상규균미발생명현개변,무기타불량반응。결론련화청온효낭능현저개선만성조새성폐질병환자적림상료효,능유효억제염성인자석방,종이감경기도염성반응작용。
Objective To investigate the effect of the Lianhuaqingwen capsules on the pulmonary function , blood gas index and inflammatory factor tumor necrosis factor alpha (TNF-alpha),interleukin 8 (IL-8) and IL-17 in patients with chron-ic obstructive pulmonary disease (COPD).Methods From January 2014 to February 2015, 72 cases inpatient or outpatients who received treatment for chronic obstructive pulmonary disease were enrolled .They were randomly divided into 2 groups ac-cording to the random number table , 36 cases in each group .The control group was given conventional treatment , the observa-tion group on the basis of treatment in the control group , also added Lianhuaqingwen capsules;treatment lasted for 10 days. Then observed the clinical curative effect of 2 groups of patients, lung function and blood gas index and level of TNF-α,IL-8 and IL-17 level changes were compared .Results The total efficiency of observation group was significantly higher than that of the control group (94.4%vs.72.2%,χ2 =17.71, P <0.05);after treatment, the 2 groups’ patients’ pulmonary func-tion index, forced expiratory volume in one second ( FEV1 ) , FEV1/FVC ratio ( FEV1/FVC) , blood gas indexes ( PaO2 ) , partial pressure of carbon dioxide ( PaCO2 ) , TNF-α,IL-8 and IL-17 levels were significantly improved compared with before treatment, the difference was statistically significant ( P <0.05) between the 2 groups, the observation group’s improvement was better than the control group , the difference was statistically significant ( P <0.05); the 2 groups’ pH value did not change significantly before and after treatment ( P >0.05), during treatment, 2 groups’ patients’ heart rate, blood pressure and blood urine routine , liver and kidney function were not changed significantly , no other adverse reactions were found .Con-clusion Lianhuaqingwen capsules can significantly improve the clinical efficacy of patients with chronic obstructive pulmo -nary disease ( COPD) , it can effectively inhibit the release of inflammatory cytokines , thereby reducing airway inflammatory reaction.